This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs
by Sweta Killa
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
JNJPositive Net Change PFENegative Net Change MRNAPositive Net Change BIBNegative Net Change TRILNegative Net Change LABUNegative Net Change
biotechs etfs
Moderna (MRNA) Seeks Full FDA Approval for COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) completes rolling submission of BLA to the FDA seeking full approval of its COVID-19 vaccine candidate, mRNA-1273, in the United States.
JNJPositive Net Change PFENegative Net Change MRNAPositive Net Change BNTXNegative Net Change
biotechs messenger-rna
The Zacks Analyst Blog Highlights: Apple, Regeneron Pharmaceuticals, TJX Companies, Moderna and NVIDIA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Regeneron Pharmaceuticals, TJX Companies, Moderna and NVIDIA
REGNPositive Net Change AAPLNegative Net Change TJXPositive Net Change NVDANegative Net Change MRNAPositive Net Change
biotechs computers medical retail semiconductor tech-stocks
Stealth (MITO) Files NDA for Ultra-Rare Disease Candidate
by Zacks Equity Research
Stealth BioTherapeutics (MITO) files a new drug application for elamipretide to the FDA for the treatment of Barth syndrome, an ultra-rare genetic condition.
VRTXNegative Net Change CRVSNegative Net Change SPROPositive Net Change MITONegative Net Change
biotechs
Regeneron's (REGN) Wet AMD Study on High Dose Eylea Meets Goal
by Zacks Equity Research
Regeneron's (REGN) phase II study evaluating a higher 8-mg dose of Eylea injection in patients with wet age-related macular degeneration has met the primary safety endpoint.
REGNPositive Net Change NVSNo Net Change BAYRYNegative Net Change HZNPPositive Net Change
biotechs
Vertex (VRTX) Inks New Deal for CRISPR Gene-Editing Rights
by Zacks Equity Research
Vertex (VRTX) collaboration with Arbor will support discovery & development of new treatment options for serious diseases using the latter's CRISPR technology.
VRTXNegative Net Change MRNAPositive Net Change CRSPNegative Net Change KYMRNegative Net Change
biotechs gene-editing
Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs
by Sweta Jaiswal, FRM
The biotech space has once again come under the spotlight as the FDA has granted the first full U.S. approval to Pfizer (PFE)/BioNTech's (BNTX) coronavirus vaccine.
PFENegative Net Change IBBNegative Net Change XBINegative Net Change BBHPositive Net Change FBTNegative Net Change BTECPositive Net Change BNTXNegative Net Change
biotechnology biotechs etfs vaccines
Bristol Myers' (BMY) sBLA for Orencia Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) sBLA for Orencia under a priority review to prevent moderate to severe acute graft versus host disease. A verdict is pending on Dec 23, 2021.
BMYNegative Net Change VRTXNegative Net Change CRVSNegative Net Change SPROPositive Net Change
biotechs
Dynavax (DVAX) Gains as Medigen Rolls Out COVID-19 Vaccine
by Zacks Equity Research
Dynavax (DVAX) stock gains as partner Medigen announces launch of its COVID-19 vaccine MVC-COV1901 adjuvanted with CpG 1018 of the former.
DVAXPositive Net Change PFENegative Net Change RGENNegative Net Change BNTXNegative Net Change
biotechs pharmaceuticals vaccines
Axsome's (AXSM) Stock Up Despite FDA Delay on Depression Drug
by Zacks Equity Research
FDA delays decision on Axsome Therapeutics' (AXSM) new drug application for AXS-05, a potential treatment for major depressive disorder.
REGNPositive Net Change HZNPPositive Net Change RGENNegative Net Change AXSMPositive Net Change
biotechs
CARA Drug Wins FDA Nod for Pruritus Associated With CKD
by Zacks Equity Research
CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
REGNPositive Net Change HZNPPositive Net Change RGENNegative Net Change
biotechs pharmaceuticals
3 COVID Vaccine Makers to Watch on Pfizer Jab Full FDA Approval
by Zacks Equity Research
Stocks of coronavirus vaccine makers BNTX and MRNA fly high following complete approval of Pfizer's COVID-19 vaccine. The momentum is likely to continue for these stocks. JNJ is another strong contender in this field.
JNJPositive Net Change PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechs messenger-rna pharmaceuticals
Regeneron (REGN) COVID-19 Antibody Cocktail Gets CMA in the UK
by Zacks Equity Research
Regeneron (REGN) gets Conditional Marketing Authorization for its antibody cocktail, casirivimab and imdevimab for COVID-19 infection in the United Kingdom.
REGNPositive Net Change GSKNegative Net Change RHHBYNegative Net Change VIRNegative Net Change
biotechs
Bristol Myers' (BMY) Opdivo Approved for Another Indication
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo gets label expansion in the United States for adjuvant treatment of patients with high-risk urothelial carcinoma.
REGNPositive Net Change BMYNegative Net Change HZNPPositive Net Change SGENPositive Net Change
biotechs immuno-therapy medical
Implied Volatility Surging for Humanigen (HGEN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
HGENNegative Net Change
biotechs medical
Biotech ETFs to Benefit From Latest Booster Update
by Sweta Jaiswal, FRM
The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.
PFENegative Net Change MRNAPositive Net Change IBBNegative Net Change XBINegative Net Change BBHPositive Net Change FBTNegative Net Change BTECPositive Net Change BNTXNegative Net Change
biotechs etfs vaccines
Bristol Myers (BMY) CAR T Cell Therapy Abecma Approved by EC
by Zacks Equity Research
Bristol Myers (BMY) wins EC approval for its CAR T cell immunotherapy, Abecma, for the treatment of multiple myeloma.
NVSNo Net Change BMYNegative Net Change GILDPositive Net Change
biotechs pharmaceuticals
Gilead (GILD) MAA for HIV Inhibitor Under the EMA's Review
by Zacks Equity Research
Gilead's (GILD) application for an investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, is under review with the European regulatory body.
GSKNegative Net Change MRKPositive Net Change GILDPositive Net Change RGENNegative Net Change
biotechs
Is Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine is being probed for higher risk of heart inflammation compared to Pfizer's vaccine, per a Washington Post article.
JNJPositive Net Change PFENegative Net Change MRNAPositive Net Change BNTXNegative Net Change
biotechs messenger-rna
New Strong Sell Stocks for August 20th
by Zacks Equity Research
ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
TRVNNo Net Change CSSENegative Net Change HSDTNegative Net Change ADXNPositive Net Change LYRANegative Net Change
biotechs consumer-discretionary medical
Do Options Traders Know Something About Sesen Bio (SESN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.
SESNPositive Net Change
biotechs medical
Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM
by Zacks Equity Research
The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.
VRTXNegative Net Change RGENNegative Net Change PRTKPositive Net Change CRVSNegative Net Change
biotechs
Regeneron (REGN) Antibody Cocktail for COVID-19 Gets a Boost
by Zacks Equity Research
Regeneron (REGN) antibody cocktail for COVID-19 receives a boost as the Governor of Florida recommends it for COVID-19 treatment.
REGNPositive Net Change GSKNegative Net Change LLYNegative Net Change VIRNegative Net Change
biotechs
Coherus (CHRS), Junshi Announce Positive NSCLC Study Results
by Zacks Equity Research
Coherus BioSciences (CHRS) and partner Junshi announce positive data from a late-stage study on toripalimab for the first-line treatment of NSCLC.
RHHBYNegative Net Change BMYNegative Net Change MRKPositive Net Change CHRSNegative Net Change
biotechs
Werewolf (HOWL) Up on Deal With Merck for Solid Tumor Study
by Zacks Equity Research
Werewolf Therapeutics (HOWL) inks a collaboration and supply agreement with Merck to evaluate its candidate, WTX-124, in combination with Keytruda, for treating solid tumors. Stock up.
MRKPositive Net Change VRTXNegative Net Change RGENNegative Net Change HOWLNegative Net Change
biotechs